**Table S1. Univariable comparison of retention (n = 408)**

|  |  |  |  |
| --- | --- | --- | --- |
| Mean (± SD) for continuous variables; % (n) for categorical variables | Baseline only (n = 150) | Baseline and 3 months (n = 258) | P-value |
| **Knowledge about harms and benefits**  |  |  |  |
| Yes | 12.6 (17) | 17.3 (43) | 0.242 |
| No | 87.4 (118) | 82.7 (205) |  |
| **Satisfaction with healthcare professional** |  |  |  |
| Satisfaction score, mean ± SD | 19.30 ± 3.68 | 19.30 ± 3.83 | 0.987 |
| **Received a leaflet about tamoxifen** |  |  |  |
| Yes | 68.0 (102) | 72.9 (188) | 0.310 |
| No/unsure | 32.0 (48) | 27.1 (70) |  |
| **Felt informed about tamoxifen** |  |  |  |
| Yes | 80.3 (118) | 91.0 (233) | **0.003** |
| No | 19.7 (29) | 9.0 (23) |  |

P-value tests for significant differences between the ‘baseline’ and ‘baseline and 3-month’ cohorts using tests and t-tests.

**Table S2. Sensitivity analysis: Knowledge about benefits and ≥ 2 harms of tamoxifen by participant characteristics and univariable and multivariable logistic regression model (n =317)**

|  |  |  |
| --- | --- | --- |
| **Knowledge about benefits and ≥ 2 harms of tamoxifen (%; N)** | **Univariable** | **Multivariable** |
| **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| **Age** |  |  |  |  |  |
|  ≤ 35 years | 25.6 (10) | 0.78 (0.34 – 1.79) | 0.556 | 0.73 (0.23 – 2.26) | 0.579 |
|  36 – 49 years | 32.9 (80) | 1.11 (0.67 – 1.83) | 0.687 | 0.71 (0.37 – 1.36) | 0.303 |
|  ≥ 50 years | 30.7 (31) | Ref |  | Ref |  |
| **Children**  |  |  |  |  |  |
|  Yes | 33.1 (98) | 1.38 (0.81 – 2.35) | 0.240 | 1.61 (0.76 – 3.41) | 0.219 |
|  No | 26.4 (23) | Ref |  | Ref |  |
| **Ethnic group**\* |  |  |  |  |  |
|  White | 31.2 (114) | - | **-** | - | - |
|  Other | 42.9 (6) | - | - | - | - |
| **Education level** |  |  |  |  |  |
|  Degree or above | 43.3 (74) | 2.67 (1.71 – 4.17) | **≤ 0.001** | 2.95 (1.68 – 5.18) | **≤ 0.001** |
|  Below degree level | 22.2 (46) | Ref |  | Ref |  |
| **Health status** |  |  |  |  |  |
|  Poor\* | 33.3 (5) | - | - | - | - |
|  Fair | 16.2 (12) | 0.39 (0.17 – 0.88) | **0.023** | 0.47 (0.18 – 1.18) | 0.108 |
|  Good | 36.2 (83) | 1.14 (0.62 – 2.07) | 0.675 | 1.14 (0.57 – 2.29) | 0.713 |
|  Excellent | 33.3 (20) | Ref |  | Ref |  |
| **Risk level** |  |  |  |  |  |
|  Moderate | 35.5 (81) | 1.57 (1.00 – 2.47) | 0.052 | 1.79 (1.03 – 3.14) | **0.041** |
|  High  | 26.0 (39) | Ref |  | Ref |  |
|  Unclear\* | 20.0 (1) | - | - | - | - |
| **SES** |  |  |  |  |  |
|  Low (most deprived) | 28.6 (32) | 0.77 (0.45 – 1.33) | 0.354 | 1.06 (0.55 – 2.04) | 0.860 |
|  Middle  | 31.5 (40) | 0.89 (0.53 – 1.49) | 0.657 | 0.900 (0.48 – 1.70) | 0.742 |
|  High (least deprived) | 34.1 (47) | Ref |  | Ref |  |
| **Employment** |  |  |  |  |  |
|  Full-time | 31.0 (102) | Ref |  | Ref |  |
|  All other employments | 35.2 (19) | 1.21 (0.66 – 2.21) | 0.540 | 1.88 (0.91 – 3.90) | 0.089 |
| **Marital status** |  |  |  |  |  |
|  Married or cohabiting | 32.3 (91) | 1.06 (0.65 – 1.75) | 0.807 | 1.15 (0.59 – 2.26) | 0.686 |
|  Unmarried | 30.9 (30) | Ref |  | Ref |  |
| **Numeracy** |  |  |  |  |  |
| Good numeracy | 34.0 (104) | 1.99 (1.05 – 3.74) | **0.034** | 2.43 (1.09 – 5.40) | **0.030** |
| Poor numeracy | 20.6 (14) | Ref |  | Ref |  |
| **Received a leaflet about tamoxifen** |  |  |  |  |  |
| Yes | 34.7 (95) | 1.69 (1.02 – 2.81) | **0.041** | 1.14 (0.61 – 2.12) | 0.684 |
| No/unsure  | 23.9 (26) | Ref |  | Ref |  |
| **Satisfaction with healthcare professional**  |  |  |  |  |  |
| Satisfaction score, mean ± SD | 19.44 (3.44) | 1.02 (0.96 – 1.08) | 0.629 | 0.99 (0.93 – 1.07) | 0.836 |
| **Felt informed about tamoxifen** |  |  |  |  |  |
| Yes | 34.5 (115) | 3.69 (1.52 – 8.95) | **0.004** | 3.73 (1.18 – 11.79) | **0.025** |
| No | 12.5 (6) | Ref |  | Ref |  |

\*category not included in univariable and multivariable analyses due to insufficient cases.

 += This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and at least two of the three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer). In total, 31.6% (121) of women identified the benefit and ≥ 2 harms of tamoxifen.

**Table S3. Knowledge about the potential harms and benefits of tamoxifen by participant characteristics and univariable and multivariable logistic regression model, with missing data reported as poor knowledge (n=332)**

|  |  |  |
| --- | --- | --- |
| **Good knowledge+ (%; N)** | **Univariable** | **Multivariable** |
| **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| **Age** |  |  |  |  |  |
|  ≤ 35 years | 9.8 (4) | 0.66 (0.21 – 2.13) | 0.490 | 0.50 (0.11 – 2.43) | 0.393 |
|  36 – 49 years | 15.8 (41) | 1.18 (0.62 – 2.24) | 0.611 | 0.69 (0.30 – 1.59) | 0.387 |
|  ≥ 50 years | 13.9 (15) | Ref |  | Ref |  |
| **Children**  |  |  |  |  |  |
|  Yes | 15.3 (48) | 1.23 (0.63 – 2.43) | 0.545 | 1.47 (0.57 – 3.76) | 0.425 |
|  No | 12.8 (12) | Ref |  | Ref |  |
| **Ethnic group**\* |  |  |  |  |  |
|  White | 14.3 (55) | - | **-** | - | - |
|  Other | 22.2 (4) | - | - | - | - |
| **Education level** |  |  |  |  |  |
|  Degree or above | 21.6 (38) | 2.50 (1.42 – 4.42) | **0.002** | 2.47 (1.23 – 4.97) | **0.011** |
|  Below degree level | 9.9 (22) | Ref |  | Ref |  |
| **Health status** |  |  |  |  |  |
|  Poor\* | 18.8 (3) | - | - | -  | - |
|  Fair | 6.4 (5) | 0.38 (0.12 – 1.19) | 0.096 | 0.40 (0.11 – 1.46) | 0.166 |
|  Good | 17.5 (42) | 1.19 (0.56 – 2.52) | 0.653 | 1.16 (0.50 – 2.68) | 0.737 |
|  Excellent | 15.2 (10) | Ref |  | Ref |  |
| **Risk level** |  |  |  |  |  |
|  Moderate | 17.7 (43) | 1.80 (0.98 – 3.28) | 0.056 | 1.94 (0.94 – 4.00) | 0.075 |
|  High  | 10.7 (17) | Ref |  | Ref |  |
|  Unclear\* | 0.0 (0) | - | - | - | - |
| **SES** |  |  |  |  |  |
|  Low (most deprived) | 13.3 (16) | 0.84 (0.42 – 1.68) | 0.630 | 1.01 (0.44 – 2.29) | 0.986 |
|  Middle  | 14.5 (19) | 0.95 (0.49 – 1.83)  | 0.872 | 0.93 (0.42 – 2.06) | 0.862 |
|  High (least deprived) | 15.3 (23) | Ref |  | Ref |  |
| **Employment** |  |  |  |  |  |
|  Full-time | 15.2 (53) | Ref |  | Ref |  |
|  All other employments | 11.7 (7) | 0.72 (0.31 – 1.67) | 0.444 | 1.13 (0.44 – 2.91) | 0.799 |
| **Marital status** |  |  |  |  |  |
|  Married or cohabiting | 15.4 (46) | 1.14 (0.59 – 2.17) | 0.701 | 1.00 (0.44 – 2.29) | 0.998 |
|  Unmarried | 13.6 (14) | Ref |  | Ref |  |
| **Numeracy** |  |  |  |  |  |
| Good numeracy | 18.0 (58) | 7.70 (1.83 – 32.30) | **0.005** | 6.14 (1.39 – 27.09) | **0.017** |
| Poor numeracy | 2.8 (2) | Ref |  | Ref |  |
| **Received a leaflet about tamoxifen** |  |  |  |  |  |
| Yes | 16.9 (49) | 1.98 (0.99 – 3.95) | 0.054 | 1.52 (0.65 – 3.55) | 0.334 |
| No/unsure  | 9.3 (11) | Ref |  | Ref |  |
| **Satisfaction with healthcare professional**  |  |  |  |  |  |
| Satisfaction score, mean ± SD | 19.34 ± 3.55 | 1.00 (0.93 – 1.08) | 0.936 | 0.97 (0.89 – 1.06) | 0.554 |
| **Felt informed about tamoxifen** |  |  |  |  |  |
| Yes | 16.5 (58) | 4.95 (1.17 – 20.91) | **0.030** | 5.49 (0.69 – 43.73) | 0.108 |
| No | 3.8 (2) | Ref |  | Ref |  |

\*category not included in univariable and multivariable analyses due to insufficient cases.

 += This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of tamoxifen (increased risk of menopausal symptoms, blood clotting and endometrial cancer).

**Table S4. Still deciding about tamoxifen on the subjective decision quality scale, by participant characteristics and univariable and multivariable logistic regression model (n=216)**

|  |  |  |
| --- | --- | --- |
| **Still deciding (%; N)** | **Univariable** | **Multivariable** |
| **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| **Age** |  |  |  |  |  |
|  ≤ 35 years | 37.0 (10) | 0.55 (0.22 – 1.40) | 0.208 | 0.57 (0.17 – 1.91) | 0.361 |
|  36 – 49 years | 41.1 (69) | 0.65 (0.36 – 1.17) | 0.154 | 0.70 (0.34 – 1.44) | 0.334 |
|  ≥ 50 years | 51.6 (32) | Ref |  | Ref |  |
| **Children**  |  |  |  |  |  |
|  Yes | 43.8 (89) | 1.14 (0.62 – 2.09) | 0.683 | 0.94 (0.41 – 2.15) | 0.878 |
|  No | 40.7 (22) | Ref |  | Ref |  |
| **Ethnic group** |  |  |  |  |  |
|  White | 43.1 (106) | 1.51 (0.37 – 6.19) | 0.564 | 1.02 (0.21 – 5.05) | 0.983 |
|  Other | 33.3 (3) | Ref |  | Ref |  |
| **Education level** |  |  |  |  |  |
|  Degree or above | 35.9 (42) | 0.59 (0.35 – 0.97) | **0.037** | 0.72 (0.38 – 1.39) | 0.329 |
|  Below degree level | 48.9 (68) | Ref |  | Ref |  |
| **Health status** |  |  |  |  |  |
|  Poor | 45.5 (5) | 1.62 (0.43 – 6.11) | 0.481 | 2.92 (0.58 – 14.60) | 0.193 |
|  Fair | 44.7 (21) | 1.57 (0.68 – 3.60) | 0.292 | 1.56 (0.59 – 4.14) | 0.373 |
|  Good | 45.3 (68) | 1.61 (0.81 – 3.18) | 0.174 | 1.31 (0.58 – 2.96) | 0.512 |
|  Excellent | 34.0 (16) | Ref |  | Ref |  |
| **Risk level** |  |  |  |  |  |
|  Moderate | 37.6 (59) | 0.58 (0.35 – 0.96) | **0.035** | 0.70 (0.38 – 1.29) | 0.251 |
|  High  | 51.0 (50) | Ref |  | Ref |  |
|  Unclear\* | 2 (100) | - | - | - | - |
| **SES** |  |  |  |  |  |
|  Low (most deprived) | 45.9 (28) | 1.08 (0.58 – 2.04) | 0.804 | 0.69 (0.31 – 1.52) | 0.360 |
|  Middle  | 40.0 (34) | 0.85 (0.48 – 1.52) | 0.584 | 0.55 (0.27 – 1.13) | 0.105 |
|  High (least deprived) | 43.9 (47) | Ref |  | Ref |  |
| **Employment** |  |  |  |  |  |
|  Full-time | 43.2 (95) | Ref |  | Ref |  |
|  All other employments | 43.2 (16) | 1.00 (0.50 – 2.03) | 0.994 | 1.07 (0.47 – 2.48) | 0.868 |
| **Marital status** |  |  |  |  |  |
|  Married or cohabiting | 41.6 (82) | 0.74 (0.41 – 1.32) | 0.307 | 0.96 (0.44 – 2.06) | 0.909 |
|  Unmarried | 49.2 (29) | Ref |  | Ref |  |
| **Numeracy** |  |  |  |  |  |
| Good numeracy | 42.3 (88) | 0.84 (0.44 – 1.63) | 0.613 | 1.03 (0.46 – 2.33) | 0.940 |
| Poor numeracy | 46.5 (20) | Ref |  | Ref |  |
| **Received a leaflet about tamoxifen** |  |  |  |  |  |
| Yes | 44.4 (83) | 1.20 (0.69 – 2.09) | 0.528 | 1.22 (0.61 – 2.45) | 0.573 |
| No/unsure  | 40.0 (28) | Ref |  | Ref |  |
| **Satisfaction with healthcare professional**  |  |  |  |  |  |
| Satisfaction score, mean ± SD | 18.28 ± 3.57 | 0.88 (0.82 – 0.95) | **0.001** | 0.88 (0.81 – 0.96) | **0.003** |
| **Felt informed about tamoxifen** |  |  |  |  |  |
| Yes | 40.8 (95) | 0.37 (0.15 – 0.90) | **0.029** | 0.64 (0.21 – 1.90) | 0.419 |
| No | 65.2 (15) | Ref |  | Ref |  |
| **Knowledge about harms and benefits** |  |  |  |  |  |
| Yes | 38.6 (17) | 0.81 (0.41 – 1.57) | 0.522 | 1.04 (0.47 – 2.33) | 0.919 |
| No | 43.9 (90) | Ref |  | Ref |  |

\*category not included in univariable and multivariable analyses due to insufficient cases.